Carmustine Accordpharma (BCNU)
Alkylating nitrosourea chemotherapy agent for brain tumors, lymphomas, and myeloma
Carmustine Accordpharma is a cytotoxic alkylating chemotherapy drug belonging to the nitrosourea class. It is administered by intravenous infusion and is used to treat brain tumors (including glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, and ependymoma), Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. Carmustine is particularly valuable in neuro-oncology because it crosses the blood–brain barrier. Treatment must be supervised by a specialist oncologist with regular monitoring of blood counts, lung function, liver, and kidney function due to the risk of delayed myelosuppression and cumulative organ toxicity.
Quick Facts
Key Takeaways
- Carmustine (BCNU) is a nitrosourea chemotherapy drug that crosses the blood–brain barrier, making it uniquely effective for treating brain tumors and central nervous system malignancies.
- Bone marrow suppression is delayed (nadir at 4–6 weeks) and cumulative—treatment cycles are typically spaced 6 weeks apart with mandatory blood count monitoring.
- Pulmonary toxicity is a serious long-term risk, especially with cumulative doses exceeding 1,400 mg/m²; lung function must be monitored during and for years after treatment.
- Carmustine must not be used during pregnancy or breastfeeding; effective contraception is required for both male and female patients during and after treatment.
- The drug is administered as a slow intravenous infusion over 1–2 hours and must never be given as a rapid injection due to the risk of severe venous pain and tissue damage.
What Is Carmustine Accordpharma and What Is It Used For?
Carmustine, also known as BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), is a bifunctional alkylating agent that has been a cornerstone of cancer treatment since its development in the 1960s. It belongs to the nitrosourea family of chemotherapy drugs, which are characterized by their lipophilic (fat-soluble) nature and their unique ability to cross the blood–brain barrier—a property that makes them particularly valuable in the treatment of central nervous system (CNS) malignancies. Carmustine Accordpharma is a branded generic formulation manufactured by Accord Healthcare, supplied as a powder and solvent for concentrate for solution for infusion, with each vial containing 50 mg of carmustine.
The mechanism of action of carmustine involves two primary biochemical processes. First, it alkylates DNA by forming interstrand and intrastrand cross-links, primarily at the O-6 position of guanine residues. These cross-links prevent the DNA strands from being properly separated and replicated during cell division, ultimately triggering programmed cell death (apoptosis). Second, carmustine carbamoylates proteins, particularly those involved in DNA repair mechanisms. By inhibiting the enzymes that would normally repair DNA damage, carmustine enhances its own cytotoxic effect. This dual mechanism makes carmustine effective against both rapidly dividing and slower-growing cancer cells, and it is considered cell cycle non-specific.
In the treatment of brain tumors, carmustine has been one of the most widely used chemotherapy agents for decades. It is effective against a broad spectrum of primary CNS tumors, including glioblastoma multiforme (the most aggressive form of brain cancer), brainstem glioma, medulloblastoma, astrocytoma, and ependymoma. It is also used for metastatic brain tumors that have spread from other parts of the body. The ability of carmustine to penetrate the blood–brain barrier is critical, as most chemotherapy drugs cannot effectively reach tumors within the brain and spinal cord. According to the National Comprehensive Cancer Network (NCCN) guidelines, carmustine-based regimens remain an important part of the treatment landscape for high-grade gliomas, particularly in combination with other agents or following surgical resection and radiation therapy.
For Hodgkin lymphoma, carmustine is a key component of the BEAM conditioning regimen (BCNU, etoposide, cytarabine, melphalan) used before autologous stem cell transplantation. This intensive chemotherapy protocol is used for patients with relapsed or refractory Hodgkin lymphoma and has been shown to significantly improve long-term survival rates. In non-Hodgkin lymphoma, carmustine may be used as part of various combination chemotherapy regimens, depending on the specific subtype and stage of the disease. For multiple myeloma, carmustine-containing regimens may be considered in certain clinical situations, though newer targeted therapies have expanded the treatment landscape considerably.
Carmustine may also be used in combination with other chemotherapy drugs and radiation therapy for other types of cancer. In some specialized centers, carmustine wafers (a different formulation known as Gliadel) are implanted directly into the surgical cavity after brain tumor removal to provide sustained local drug delivery. However, the intravenous formulation described here (Carmustine Accordpharma) is the systemic treatment form and is the focus of this article.
Carmustine Accordpharma must only be prescribed and administered by physicians experienced in cancer chemotherapy, in a hospital or specialized oncology unit equipped for intravenous chemotherapy administration. The dosage is carefully individualized based on body surface area, blood counts, organ function, and the specific cancer being treated. Never start, stop, or change treatment without your oncologist’s guidance.
What Should You Know Before Receiving Carmustine?
Before your oncologist prescribes carmustine, a comprehensive medical evaluation is essential. This includes a complete blood count with differential, pulmonary function tests (including diffusion capacity for carbon monoxide, DLCO), liver function tests, kidney function tests, and a detailed review of your complete medical history and all medications you are currently taking. These baseline assessments are critical for determining whether carmustine is safe and appropriate for your individual situation, and they serve as reference points for monitoring during treatment.
Contraindications
There are specific situations in which carmustine must not be used. Understanding these contraindications is vital for patient safety:
- Hypersensitivity: Do not receive carmustine if you have a known allergy to carmustine, other nitrosourea drugs (such as lomustine or streptozotocin), or any of the excipients in the formulation.
- Severe bone marrow suppression: Carmustine is contraindicated in patients with severely depressed bone marrow function, as the drug would further suppress the already compromised bone marrow, leading to life-threatening infections, bleeding, or severe anemia.
- Pregnancy and breastfeeding: Carmustine is teratogenic and embryotoxic and must not be used during pregnancy. Breastfeeding is also contraindicated during and after treatment.
Warnings and Precautions
Several important precautions must be carefully considered before and during treatment with carmustine. Discuss the following with your oncologist:
- Delayed bone marrow suppression: Unlike most chemotherapy drugs, carmustine causes delayed myelosuppression. White blood cell and platelet counts typically reach their lowest point (nadir) 4–6 weeks after administration, which is considerably later than with most other cytotoxic agents. This delayed effect is cumulative, meaning that with each subsequent treatment cycle, the bone marrow may take progressively longer to recover. Blood counts must be monitored weekly for at least 6 weeks after each dose, and the next treatment cycle should not begin until blood counts have recovered sufficiently.
- Pulmonary toxicity: Carmustine can cause serious lung damage, including pulmonary fibrosis and interstitial pneumonitis. This risk is related to the cumulative dose and is particularly significant when the total lifetime dose exceeds 1,400 mg/m². However, pulmonary toxicity can occur at lower doses as well. Lung damage may manifest months or even years after treatment has ended. Baseline pulmonary function tests (including DLCO) should be performed before starting treatment and repeated periodically during and after treatment. Patients with pre-existing lung disease are at higher risk and require especially careful monitoring.
- Hepatotoxicity: Carmustine can cause liver damage, including elevated liver enzymes, hepatitis, and in rare cases, hepatic veno-occlusive disease. Liver function tests should be monitored regularly during treatment. Patients with pre-existing liver disease may require dose adjustments or alternative therapies.
- Nephrotoxicity: Kidney damage has been reported with carmustine, particularly with prolonged treatment or high cumulative doses. Kidney function should be assessed before each treatment cycle. Patients with pre-existing renal impairment require careful dose adjustment and more frequent monitoring.
- Recent radiotherapy or chemotherapy: If you have recently received radiation treatment or other myelosuppressive chemotherapy, your bone marrow reserve may already be reduced. Your oncologist will carefully assess your blood counts and may delay carmustine treatment until adequate recovery has occurred.
- Vaccination: Live vaccines (such as measles, mumps, rubella, oral polio, yellow fever, and BCG) must be avoided during treatment with carmustine and for a period afterward. The immunosuppressive effect of carmustine means that live vaccines could cause serious or potentially fatal infections. Inactivated vaccines may be given but may produce a diminished immune response.
- Secondary malignancies: As with other alkylating agents, carmustine may increase the risk of developing secondary cancers, including acute leukemia and myelodysplastic syndrome, particularly with prolonged treatment or high cumulative doses.
Carmustine can cause fatal pulmonary toxicity. Pulmonary fibrosis has been reported to occur up to 17 years after treatment. The risk increases significantly with cumulative doses above 1,400 mg/m², but cases have occurred at lower doses. Patients who received carmustine in childhood or adolescence are at particular risk for delayed pulmonary fibrosis. Lung function monitoring must continue for years after treatment completion.
Pregnancy and Breastfeeding
Carmustine poses serious risks to reproductive health and to an unborn child. The following guidelines are essential:
Pregnancy: Carmustine is teratogenic and embryotoxic in animal studies and must not be used during pregnancy. It can cause severe birth defects, fetal growth restriction, and fetal death. If you are pregnant or become pregnant during treatment, inform your oncologist immediately. Effective and reliable contraception is mandatory:
- Female patients: Use highly effective contraception during treatment and for at least 6 months after the last dose of carmustine.
- Male patients: Use effective contraception during treatment and for at least 3 months after the last dose, as carmustine can damage sperm DNA.
Breastfeeding: It is not known whether carmustine or its metabolites are excreted in human breast milk. Given its cytotoxic nature, breastfeeding must be discontinued during treatment and should not be resumed after treatment completion without consulting your oncologist.
Fertility: Carmustine can significantly affect fertility in both men and women. In women, it may cause ovarian damage leading to premature ovarian insufficiency, amenorrhea, and permanent infertility. In men, it can cause azoospermia (absence of sperm), which may be temporary or permanent depending on the cumulative dose and duration of treatment. Patients who wish to have children in the future should discuss fertility preservation options (sperm banking, egg or embryo freezing) with their oncologist before starting treatment.
Driving and Operating Machinery
There are no specific studies on the effect of carmustine on driving ability. However, chemotherapy commonly causes side effects such as nausea, vomiting, fatigue, and dizziness that can impair alertness and reaction times. Patients should not drive or operate heavy machinery on the day of infusion and should assess their own fitness to drive during the treatment period. If you experience any symptoms that could impair your ability to drive safely, avoid driving and consult your oncologist.
How Does Carmustine Interact with Other Drugs?
Drug interactions can significantly affect the safety and efficacy of carmustine therapy. Some interactions may increase the risk of serious toxicity, while others may reduce the effectiveness of carmustine or of concomitant medications. Your oncologist and clinical pharmacist will carefully review all your current medications before each treatment cycle to identify and manage potential interactions.
Major Interactions
| Drug | Interaction | Clinical Significance |
|---|---|---|
| Phenytoin (anticonvulsant) | Carmustine may reduce phenytoin plasma levels, leading to decreased seizure control. This is especially important in brain tumor patients who often require anticonvulsant therapy. | Monitor phenytoin levels closely; dose adjustment may be needed. Consider alternative anticonvulsants such as levetiracetam. |
| Cimetidine (H2 blocker) | Cimetidine may enhance the bone marrow suppressive effects of carmustine by inhibiting its hepatic metabolism, leading to higher drug levels and more severe myelotoxicity. | Avoid concurrent use if possible. Use alternative acid-suppressing agents such as ranitidine, famotidine, or proton pump inhibitors. |
| Digoxin (cardiac glycoside) | Carmustine-containing chemotherapy regimens may reduce the gastrointestinal absorption of digoxin, leading to subtherapeutic levels and loss of cardiac effect. | Monitor digoxin levels during and after carmustine treatment. Consider using the capsule formulation of digoxin or adjust the dose accordingly. |
| Live vaccines (e.g., MMR, oral polio, yellow fever, BCG) | Risk of severe or fatal vaccine-induced infection in immunocompromised patients receiving carmustine. | Contraindicated during treatment. Wait until immune recovery is confirmed before vaccination with live agents. |
| Melphalan and other alkylating agents | Additive bone marrow suppression and increased risk of pulmonary toxicity when used in combination or sequential chemotherapy regimens. | Careful dose scheduling and enhanced monitoring of blood counts and lung function required in combination protocols such as BEAM. |
Other Considerations
Beyond the major interactions listed above, additional pharmacological considerations include:
- Other myelosuppressive agents: Concurrent use of other drugs that suppress bone marrow function (including other chemotherapy drugs, certain antibiotics, and immunosuppressants) may compound the risk of severe and prolonged blood count depression. This cumulative effect requires careful treatment scheduling and enhanced monitoring.
- Nephrotoxic drugs: Medications that can harm the kidneys, such as aminoglycoside antibiotics, amphotericin B, cisplatin, or NSAIDs, may increase the risk of carmustine-related nephrotoxicity. Renal function should be closely monitored when these drugs are used concurrently.
- Hepatotoxic drugs: Concurrent use of other hepatotoxic medications may increase the risk of liver damage. Liver function should be monitored more frequently when carmustine is combined with potentially hepatotoxic drugs.
- Corticosteroids: While corticosteroids (such as dexamethasone) are frequently co-administered with carmustine in brain tumor treatment to reduce cerebral edema, they may also affect the immune response and potentially modify carmustine toxicity. Your oncologist will balance these considerations.
Always provide your oncologist and pharmacist with a complete list of all medications you are taking, including over-the-counter drugs, vitamins, dietary supplements, and herbal products. This is essential for preventing dangerous interactions and ensuring the most effective and safe treatment possible.
What Is the Correct Dosage of Carmustine?
The dosing of carmustine is carefully calculated and individualized by your treating oncologist based on your body surface area (BSA), overall health status, blood counts, organ function, and the specific type and stage of cancer being treated. Because carmustine causes delayed and cumulative bone marrow suppression, treatment cycles are spaced at least 6 weeks apart to allow time for bone marrow recovery. Your oncologist will monitor your blood counts weekly during this interval and may further adjust the dose or delay the next cycle if recovery is incomplete.
Adult Dosage
Single-Agent Therapy
Standard dose: 150–200 mg/m² body surface area as a single intravenous infusion.
Alternative schedule: The total dose may be divided equally over 2 consecutive days (e.g., 75–100 mg/m²/day for 2 days).
Treatment cycle: Repeated every 6 weeks, provided blood counts have recovered sufficiently. The white blood cell count should be above 4,000/µL and the platelet count above 100,000/µL before the next cycle begins.
Infusion rate: Each dose must be infused slowly over 1–2 hours. Rapid infusion causes intense burning pain at the injection site and may result in severe venous spasm.
Combination Chemotherapy (BEAM Regimen)
Indication: Autologous stem cell transplant conditioning for relapsed/refractory Hodgkin and non-Hodgkin lymphoma.
BCNU dose in BEAM: 300 mg/m² on day −6 (six days before transplant), given as a single intravenous infusion over 1–2 hours.
Other agents: Etoposide 200 mg/m² on days −5 to −2, cytarabine 200 mg/m² twice daily on days −5 to −2, melphalan 140 mg/m² on day −1.
| Nadir WBC (/µL) | Nadir Platelets (/µL) | Dose Adjustment |
|---|---|---|
| > 3,000 | > 75,000 | 100% of prior dose |
| 2,000–2,999 | 25,000–74,999 | 70% of prior dose |
| < 2,000 | < 25,000 | 50% of prior dose |
Children and Adolescents
Carmustine may be used in pediatric patients for the treatment of brain tumors and lymphomas, though dosing and protocols may differ from adult regimens. Pediatric dosing is calculated based on body surface area, and treatment is always managed by a pediatric oncologist experienced in chemotherapy. Special attention must be paid to the risk of delayed pulmonary toxicity, which may manifest years or decades later. Children and adolescents who receive carmustine require lifelong monitoring of lung function.
Elderly Patients
Older adults may be more susceptible to the myelosuppressive and organ-toxic effects of carmustine. Age-related decline in kidney and liver function can affect drug clearance and increase the risk of toxicity. While there is no specific age-related dose recommendation, oncologists typically exercise greater caution with dose selection in elderly patients, often starting at the lower end of the dosing range and monitoring blood counts and organ function more closely. The risk-benefit assessment should take into account the patient’s overall functional status and comorbidities.
How Carmustine Is Administered
- Carmustine is given as an intravenous infusion only. It must never be given as a rapid intravenous injection (bolus).
- The powder is first reconstituted with the supplied solvent (dehydrated alcohol), then further diluted with 0.9% sodium chloride or 5% glucose solution.
- The infusion should be administered over 1–2 hours through a freely flowing intravenous line. Shorter infusion times cause intense pain and burning at the infusion site.
- The infusion site should be monitored closely for signs of extravasation (leakage of the drug into surrounding tissue), which can cause severe local tissue damage.
- Carmustine solution is light-sensitive and should be protected from direct light during preparation and administration. The reconstituted solution has a limited stability and must be used within the time specified by the manufacturer.
Missed Dose
Since carmustine is administered in a hospital or oncology clinic setting by healthcare professionals, missed doses are uncommon. However, if a scheduled treatment is delayed or postponed due to insufficient blood count recovery or other medical reasons, your oncologist will determine the appropriate timing for the next dose based on your individual clinical status.
Overdose
In the event of an overdose, the primary concern is severe and prolonged bone marrow suppression, which may lead to life-threatening infections, hemorrhage, and severe anemia. There is no specific antidote for carmustine overdose. Management is supportive and includes intensive monitoring of blood counts, administration of blood products (platelet and red blood cell transfusions) as needed, prophylactic and therapeutic antibiotics for infections, and colony-stimulating factors to support bone marrow recovery. Hemodialysis is not effective in removing carmustine from the body due to its rapid tissue distribution and metabolism.
What Are the Side Effects of Carmustine?
Like all chemotherapy drugs, carmustine can cause significant side effects. The side effect profile of carmustine is dominated by its delayed and cumulative bone marrow suppression, which sets it apart from most other chemotherapy agents. The myelosuppression typically reaches its lowest point (nadir) 4–6 weeks after each dose, and recovery may take an additional 1–2 weeks. With successive treatment cycles, the bone marrow may take progressively longer to recover, and the severity of suppression may increase.
It is critical to contact your oncologist or seek immediate medical attention if you experience signs of severe infection (fever, chills, persistent sore throat), unusual bleeding or bruising, severe shortness of breath or persistent cough, yellowing of the skin or eyes (jaundice), decreased urine output, or signs of allergic reaction.
Very Common
May affect more than 1 in 10 patients
- Delayed bone marrow suppression: thrombocytopenia (low platelet count, nadir at 4–5 weeks) and leukopenia (low white blood cell count, nadir at 5–6 weeks)
- Nausea and vomiting (often within 2–6 hours of infusion, may be severe)
- Pain and burning at the infusion site
- Facial flushing during infusion
- Anorexia (loss of appetite)
Common
May affect up to 1 in 10 patients
- Pulmonary toxicity: interstitial pneumonitis, pulmonary fibrosis (especially with cumulative doses >1,400 mg/m²)
- Hepatotoxicity: elevated liver enzymes (AST, ALT, alkaline phosphatase, bilirubin)
- Nephrotoxicity: progressive renal failure with prolonged treatment, decreased kidney size
- Stomatitis (mouth sores and inflammation)
- Diarrhea
- Alopecia (hair loss)
- Skin hyperpigmentation at the infusion site (brown discoloration along the vein)
Uncommon
May affect up to 1 in 100 patients
- Neuro-retinal toxicity: visual disturbances, optic neuritis
- Encephalopathy (brain dysfunction) with high-dose regimens
- Secondary malignancies: acute leukemia, myelodysplastic syndrome
- Gynecomastia (breast enlargement in males)
- Allergic reactions
Rare
May affect up to 1 in 1,000 patients
- Hepatic veno-occlusive disease (blockage of small veins in the liver)
- Severe allergic or anaphylactic reactions
- Chest pain and cardiac dysfunction
- Severe skin reactions
Frequency Unknown
Reported but frequency not established
- Delayed pulmonary fibrosis occurring years or decades after treatment (especially in patients treated during childhood)
- Azoospermia and premature ovarian failure (infertility)
- Headache and dizziness
- Deep vein thrombosis and pulmonary embolism
Managing Side Effects
Many side effects of carmustine can be managed with appropriate supportive care. Your oncology team will prescribe anti-emetic medications (such as ondansetron and dexamethasone) before and after the infusion to help prevent and control nausea and vomiting. Maintaining adequate hydration before and after treatment supports kidney function and helps reduce the risk of nephrotoxicity.
For infusion-site reactions, the infusion rate can be slowed and the infusion site may be changed. Applying warm compresses to the infusion area may help relieve local discomfort. If you develop mouth sores (stomatitis), maintaining good oral hygiene with gentle mouthwashes can help reduce severity. Contact your oncology team promptly if mouth sores become severe enough to interfere with eating or drinking.
To reduce the risk of infection when your white blood cell count is low, practice thorough hand hygiene, avoid crowded places and individuals with known infections, and report any fever (even a low-grade temperature of 38°C / 100.4°F or above) immediately to your oncology team. Your oncologist may prescribe prophylactic antibiotics, antifungals, or growth factors (G-CSF) during periods of expected neutropenia to support your immune system.
- Fever or chills, even low-grade (temperature ≥38°C / 100.4°F), which may indicate infection
- Unusual bleeding or bruising, very dark stools, or blood in urine
- New or worsening shortness of breath, persistent dry cough, or chest pain
- Yellowing of skin or whites of the eyes (jaundice)
- Significant decrease in urination or swelling of the legs and feet
- Signs of allergic reaction: hives, facial or throat swelling, difficulty breathing
Reporting Side Effects
If you experience any side effects, including those not listed here, report them to your healthcare provider. You can also report suspected adverse drug reactions directly to your national pharmacovigilance authority (such as the MHRA Yellow Card Scheme in the UK, MedWatch in the US, or the EMA in Europe). Reporting side effects helps regulatory agencies continuously monitor the safety profile of medicines and contributes to drug safety for all patients.
How Should Carmustine Accordpharma Be Stored?
Proper storage and handling of carmustine is essential to maintain the drug’s potency and to prevent accidental exposure to healthcare workers, patients, and caregivers. As a cytotoxic agent, carmustine requires careful handling procedures throughout its lifecycle:
- Temperature: Store the unreconstituted vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.
- Light protection: Protect vials from light. Store in the original carton until ready for use.
- Reconstituted solution: After reconstitution, the solution has limited chemical and physical stability. Use within the timeframe specified in the product information (typically within a few hours). The reconstituted solution should also be protected from light.
- Diluted solution: The further diluted infusion solution should be administered as soon as practically possible after preparation. Follow your institution’s pharmacy guidelines for maximum storage times of prepared infusion bags.
- Visual inspection: Before use, inspect the reconstituted and diluted solution for any particles or discoloration. Do not use if the solution appears cloudy, discolored, or contains visible particles.
- Safety: Carmustine is a potent cytotoxic drug. All preparation, reconstitution, and administration must be carried out by trained personnel wearing appropriate personal protective equipment (gloves, gown, eye protection) in a designated area, ideally a cytotoxic drug safety cabinet. Pregnant healthcare workers should not handle carmustine.
- Expiration: Do not use after the expiration date printed on the vial and carton.
- Disposal: Unused drug, empty vials, and all materials that have come into contact with carmustine must be disposed of as hazardous pharmaceutical waste according to local regulations for cytotoxic drugs.
Carmustine is a vesicant agent, meaning it can cause severe tissue damage if it leaks out of the vein during infusion (extravasation). Healthcare professionals must monitor the infusion site closely throughout administration. In the event of extravasation, the infusion must be stopped immediately and appropriate treatment initiated according to institutional protocols.
What Does Carmustine Accordpharma Contain?
Active ingredient: Each vial contains 50 mg of carmustine (also known as BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea). Carmustine is the pharmacologically active component responsible for the anticancer effect.
Solvent: The product includes a separate vial of solvent (dehydrated alcohol, also called absolute ethanol) used for reconstitution. The dehydrated alcohol is necessary because carmustine has very low solubility in water and requires an organic solvent for initial dissolution. After reconstitution in the supplied solvent, the resulting concentrate must be further diluted with 0.9% sodium chloride solution or 5% glucose solution to produce the final infusion solution.
Appearance: The carmustine powder is a white to pale yellow lyophilized (freeze-dried) solid. After reconstitution with the supplied solvent, the resulting solution should be clear and colorless to pale yellow. If the reconstituted solution appears oily or contains visible particles, it should not be used, as this may indicate decomposition of the active substance.
Packaging: Carmustine Accordpharma is supplied as a carton containing one vial of carmustine 50 mg powder and one vial of solvent. The product must be stored under refrigerated conditions and protected from light as described in the storage section.
Marketing authorization holder: Accord Healthcare Limited, Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF, United Kingdom.
Frequently Asked Questions About Carmustine
Carmustine Accordpharma (BCNU) is a chemotherapy drug used to treat several types of cancer, including brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors), Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. It belongs to the nitrosourea class of alkylating agents and is particularly valuable because it can cross the blood–brain barrier, allowing it to reach tumors in the brain and central nervous system that many other chemotherapy drugs cannot effectively treat.
Unlike most chemotherapy drugs where blood count nadirs occur within 1–2 weeks, carmustine causes delayed bone marrow suppression with nadirs typically occurring 4–6 weeks after administration. This delayed toxicity is a characteristic feature of all nitrosourea drugs and is related to their unique mechanism of DNA alkylation and protein carbamoylation. The bone marrow stem cells sustain DNA damage that takes longer to manifest as reduced blood cell production. Importantly, this effect is cumulative—meaning that bone marrow recovery may take progressively longer with each treatment cycle. This is why treatment cycles are spaced at least 6 weeks apart and blood counts must be monitored weekly for the full 6-week interval.
Carmustine Accordpharma is given as a slow intravenous (IV) infusion, typically over 1 to 2 hours. It must never be given as a rapid injection. The powder in the vial is first dissolved in the supplied solvent (dehydrated alcohol), and the resulting concentrate is then further diluted with saline or glucose solution before infusion. Administration must be performed by trained healthcare professionals in a hospital or oncology clinic setting, using appropriate protective equipment. The infusion site is monitored closely throughout to detect any signs of the drug leaking into surrounding tissue (extravasation), which can cause severe local damage.
Carmustine must not be used during pregnancy as it is teratogenic (can cause birth defects) and embryotoxic (can harm or kill the developing embryo/fetus). Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose. Male patients should also use effective contraception during treatment and for at least 3 months afterward, as carmustine can damage sperm DNA. Breastfeeding is contraindicated during and after carmustine treatment. Patients who wish to have children in the future should discuss fertility preservation options with their oncologist before starting treatment.
Pulmonary (lung) toxicity is one of the most serious potential side effects of carmustine. It can manifest as interstitial pneumonitis or pulmonary fibrosis, conditions that impair the lungs' ability to transfer oxygen. The risk increases with higher cumulative doses, particularly above 1,400 mg/m², but can occur at any dose level. What makes this risk particularly concerning is that lung damage can develop months or even years after treatment has ended—cases of pulmonary fibrosis have been reported up to 17 years after carmustine treatment. Patients who received carmustine during childhood are at especially high risk. Lung function tests (including DLCO) should be performed before treatment starts and monitored periodically during and for years after treatment.
Patients receiving carmustine require comprehensive and prolonged monitoring. Blood counts (complete blood count with differential) should be checked weekly for at least 6 weeks after each dose due to the delayed nature of myelosuppression. Liver function tests (bilirubin, AST, ALT, alkaline phosphatase) and kidney function tests (serum creatinine, BUN, urine analysis) should be performed before each cycle and periodically during treatment. Pulmonary function tests, including diffusion capacity for carbon monoxide (DLCO), should be performed at baseline and repeated periodically. Chest X-rays should be obtained regularly. Monitoring of lung function should continue for years after treatment completion due to the risk of delayed pulmonary fibrosis.
References
This article is based on the following evidence-based sources and international guidelines:
- European Medicines Agency (EMA). Carmustine Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). BiCNU (carmustine) Prescribing Information. Available at: www.fda.gov. Accessed January 2026.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2.2025. www.nccn.org.
- Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005;352(10):987-996. doi:10.1056/NEJMoa043330
- British National Formulary (BNF). Carmustine drug monograph. Available at: bnf.nice.org.uk. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- Schmitz N, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease. Lancet. 2002;359(9323):2065-2071.
- O’Driscoll BR, et al. Long-term pulmonary toxicity of BCNU. British Journal of Cancer. 1990;62(2):316-318.
- Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology. 2021;18(3):170-186. doi:10.1038/s41571-020-00447-z
- Accord Healthcare Limited. Carmustine Accordpharma 50 mg, powder and solvent for concentrate for solution for infusion. Summary of Product Characteristics. Updated 2025.
Editorial Team
This article has been written and reviewed by medical professionals with expertise in oncology, hematology, and clinical pharmacology. Our editorial process follows international medical standards and the GRADE evidence framework.
iMedic Medical Editorial Team – specialists in oncology and hematology with experience in evidence-based content development for patient education.
iMedic Medical Review Board – an independent panel of board-certified physicians who review all content according to international guidelines (EMA, FDA, NCCN, ESMO, BNF).
Evidence standard: All medical claims in this article are based on Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) or established international clinical practice guidelines. This article has no pharmaceutical company sponsorship or advertising influence.
Last reviewed: | Published: